Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NAS: OPXA) , a company developing Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 6th Annual European Life Science CEO Forum on Tuesday, March 5, 2013, at 2:30 p.m. CET. The conference will be held at the Hilton Zurich Airport Hotel in Zurich, Switzerland.
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company's leading therapy, Tcelna™, is a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.
For more information, please visit the Company's website at www.opexatherapeutics.com.
KEYWORDS: United States Europe North America Texas Switzerland
The article Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.